Compugen To Receive $10M Milestone Payment Following Dosing of First Patient In AstraZeneca's Phase 3 Rilvegostomig Trial In Biliary Tract Cancer
Portfolio Pulse from Benzinga Newsdesk
Compugen will receive a $10M milestone payment as AstraZeneca begins Phase 3 trials of Rilvegostomig for Biliary Tract Cancer, following the dosing of the first patient.
January 08, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AstraZeneca commences Phase 3 trials of Rilvegostomig in Biliary Tract Cancer, triggering a $10M payment to Compugen.
For AstraZeneca, the commencement of Phase 3 trials is a routine progression in drug development. The $10M payment to Compugen is likely budgeted for and not a significant financial event for a company of AstraZeneca's size. The impact on the stock price is likely to be neutral in the short term, as investors will be more focused on the trial results rather than the payment.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 70
POSITIVE IMPACT
Compugen to receive $10M from AstraZeneca after the first patient is dosed in Phase 3 Rilvegostomig trials for cancer treatment.
The milestone payment is a significant financial event for Compugen, indicating progress in their partnership with AstraZeneca and potential future revenues if the drug is successful. This news is likely to be viewed positively by investors, potentially increasing the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100